 CAESAREA, Israel , Nov. 29, 2022 PRNewswire -- IceCure Medical Ltd. NASDAQ: ICCM TASE: ICCM IceCure or the Company, developer of minimally-invasive cryoablation technology, the ProSense System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will report its business and financial results as of and for the nine months ended September 30, 2022 on Monday, December 5, 2022 with a press release issued at 7:00 a.m. 